ArticleGynecologic oncology2022
Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.
Article in Gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Clinicopathological features and survival outcomes of HPV-independent versus HPV-associated cervical adenocarcinoma: a Systematic Review and meta-analysis.Frontiers in oncology · 2026Pooled it
- The characteristics of high-risk HPV-negative cervical cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.Journal of gynecologic oncology · 2026Trial
- Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.Gynecologic oncology · 2024Trial
- Artificial intelligence-assisted histopathological diagnosis of endocervical gastric-type adenocarcinoma: a multicenter model development and validation study.The journal of pathology. Clinical research · 2026Article
- Clinicopathological characteristics and outcomes of gastric-type adenocarcinoma of the cervix: a systematic review.AJOG global reports · 2026Review
- Clinicopathological and Prognostic Characteristics of Gastric-Type Endocervical Adenocarcinoma: A Nested Case-Control Study.Cancers · 2026Article
- Rare and uncommon tumours of the female pelvis: what the radiologist should know.The British journal of radiology · 2026Review
- Therapeutic strategy for cervical gastric-type adenocarcinoma by targeting CLU to relieve CLU-associated stress and sensitize chemotherapy.Precision clinical medicine · 2026Article
- Article
- An individualized prognostic model for survival prediction in gastric-type endocervical adenocarcinoma.Discover oncology · 2026Article
- Difficulties in Diagnosing Gastric Adenocarcinoma of the Cervix: A Clinical Case and Literature Review.Cureus · 2026Article
- Gastric-Type Cervical Adenocarcinoma: Clinicopathologic Features, Molecular Landscape, and Therapeutic Challenges.Journal of personalized medicine · 2026Review
- Article
- Mutation profile and therapeutic implications in Peutz-Jeghers syndrome-associated gastric-type endocervical adenocarcinoma.Frontiers in oncology · 2026Article
- Comprehensive clinical analysis of gastric-type endocervical adenocarcinoma: a real-world multicenter study.Annals of medicine · 2025Article
- A Comparative Analysis of Usual- and Gastric-Type Cervical Adenocarcinoma in a Japanese Population Reveals Distinct Clinicopathological and Molecular Features with Prognostic and Therapeutic Insights.International journal of molecular sciences · 2025Article
- Gastric-type endocervical adenocarcinoma in situ as the presenting feature in a mosaic STK11 pathogenic variant carrier with a Peutz-Jeghers syndrome child.Familial cancer · 2025Article
- Clinical pathological and molecular features of 100 patients with gastric-type cervical adenocarcinoma.Diagnostic pathology · 2025Article
- Immunotherapy benefits PD‑L1‑positive gastric‑type endocervical adenocarcinoma: A multicenter, retrospective study.Molecular and clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 1 institution in 1 country.
Funding
Abstract
objectivesGastric-type endocervical adenocarcinoma (GEA) is a rare form of cervical cancer not associated with human papilloma virus (HPV) infection. We summarize our experience with GEA at a large cancer center.
methodsClinical and demographic information on all patients diagnosed with GEA between June 1, 2002 and July 1, 2019 was obtained retrospectively from clinical charts. Kaplan-Meier survival analysis was performed to describe progression-free survival (PFS) and overall survival (OS). Tumors from a subset of patients underwent next generation sequencing (NGS) analysis.
resultsA total of 70 women with GEA were identified, including 43 who received initial treatment at our institution: of these 4 (9%) underwent surgery alone, 15 (35%) underwent surgery followed by adjuvant therapy, 10 (23%) were treated with definitive concurrent chemoradiation (CCRT), 7 (16%) with chemotherapy alone, and 3 (7%) with neoadjuvant CCRT and hysterectomy with or without chemotherapy. One-third (n = 14) of patients experienced disease progression, of whom 86% (n = 12) had prior CCRT. The median PFS and OS for patients with stage I GEA were 107 months (95% CI 14.8-199.2 months) and 111 months (95% CI 17-205.1 months) respectively, compared to 17 months (95% CI 5.6-28.4 months) and 33 months (95% CI 28.2-37.8 months) for patients with stages II-IV, respectively. On NGS, 4 patients (14%) had ERBB2 alterations, including 2 patients who received trastuzumab.
conclusionsGEA is an aggressive form of cervical cancer with poor PFS and OS when diagnosed at stage II or later. Further investigation is needed to identify the optimal management approach for this rare subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.